IMGN289

· ImmunoGen, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for IMGN289, covering 2015-10-02 to 2015-10-02. Get the full timeline:

Most recent: Clinical Trial Update: A Phase 1 Study of IMGN289 in Adult Patients With EGFR-positive Solid Tumors [Phase 1]